Partial
Mostly Aligned
Patient Risk:
Low
Summary
Partial alignment to the label. Correctly identifies grapefruit–atorvastatin interaction and associated muscle/liver safety concerns, but many citrus-fruit interaction claims are not supported by the label and several key label elements (e.g., comprehensive safety monitoring, contraindications, and broader indications) are not addressed.
Category Scores
Accurate Statements
Grapefruit and its juice interact with Lipitor, leading to increased levels of the medication in the body.
Contains components that inhibit CYP3A4 and can increase plasma concentrations of atorvastatin.
Increased levels of atorvastatin in the body can increase the risk of muscle damage.
Rh obligatory warning about myopathy/rhabdomyolysis with higher levels and potential drug interactions (5.1).
Increased levels of atorvastatin in the body can increase the risk of liver damage.
Liver function abnormalities and monitoring recommendations (5.2).
Consuming grapefruit or its juice while taking Lipitor can increase the risk of adverse effects.
Grapefruit interaction increases exposure; associated safety monitoring mentioned (7.2, 5.1).
Unsupported Statements
Lipitor (atorvastatin) reduces the amount of cholesterol produced in the liver.
The label discusses LDL reduction and hepatic site of action but does not explicitly state 'reduces the amount of cholesterol produced in the liver.'
Lipitor is commonly prescribed to people with high cholesterol, heart disease, or those at risk of developing these conditions.
Indication mentions use with diet in hypercholesterolemia and in patients with CHD or multiple risk factors, but the term 'commonly prescribed' is not explicitly stated.
Lipitor is available in various forms, including tablets, capsules, and a generic version.
The label only specifies tablet forms (10, 20, 40, 80 mg); capsules and generic status are not described in the provided label excerpt.
Grapefruit is the most significant citrus fruit to interact with Lipitor.
The label notes grapefruit juice inhibits CYP3A4 and increases atorvastatin exposure but does not rank citrus fruits or claim grapefruit as 'the most significant'.
Orange juice may interact with Lipitor.
No label mention of orange juice interactions; not supported by the provided label.
A study found that orange juice can increase the levels of atorvastatin in the body.
No label reference to orange juice interactions or studies.
Lemon juice may interact with Lipitor.
No label reference to lemon juice interactions.
The evidence for lemon juice interaction is limited; more research is needed to confirm the extent of this interaction.
No label reference to lemon juice interactions.
Lime juice has not been extensively studied in relation to Lipitor interactions.
No label reference to lime juice interactions.
It is essential to exercise caution when consuming lime juice while taking Lipitor.
No label reference to lime juice interactions.
Tangerine juice has been shown to interact with Lipitor, increasing the risk of adverse effects.
No label reference to tangerine juice interactions.
Kumquat juice may also interact with Lipitor, although the evidence is limited.
No label reference to kumquat juice interactions.
Satsuma mandarin juice has been shown to interact with Lipitor, increasing the risk of adverse effects.
No label reference to satsuma mandarin juice interactions.
Avoid grapefruit and its juice while taking Lipitor.
Label supports grapefruit interaction but does not explicitly instruct 'avoid' as a blanket directive.
Be cautious with orange juice; consume orange juice in moderation and monitor your body's response.
No label reference to orange juice interactions.
Exercise caution with other citrus fruits such as lemon, lime, tangerine, kumquat, and satsuma.
No label reference to these citrus interactions.
Consult your doctor or pharmacist for guidance on managing potential interactions.
While the label discusses monitoring and clinician involvement, this specific generic advice is not a discrete label claim.
Not all citrus fruits are safe to consume while taking Lipitor; exercise caution when consuming other citrus fruits.
No label reference to broader citrus-fruit safety guidance beyond grapefruit interaction.
If you're allergic to citrus fruits, consult your doctor or pharmacist for guidance on managing potential interactions; they may recommend alternative medications or adjust your dosage.
No label reference to citrus-allergy management guidance.
To minimize the risk of Lipitor interactions, consult your doctor or pharmacist for guidance on managing potential interactions; they may recommend avoiding certain foods, adjusting your dosage, or monitoring your body's response.
General guidance present in practice but not a discrete label claim; not explicitly stated in the label excerpt.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Liver function monitoring schedule (prior to and during therapy) and specific monitoring cadence (e.g., 12 weeks after initiation and dose changes, then semiannually).
Importance:
Moderate
Contraindications (e.g., active liver disease) and boxed warnings details are not explicitly covered in the claims.
Importance:
High
Detailed drug interaction management guidance (e.g., table of interacting agents with dosing adjustments) is not reflected in the claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Grapefruit interaction and hepatic/muscle safety signals are present but limited to specific claims; many citrus-interaction claims are not supported by the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Overinclusive citrus-interaction claims; lack of explicit label support for many asserted interactions and safety monitoring details.
Suggested Improvement
Restrict claims to those supported by the label (e.g., grapefruit interaction, muscle and liver safety signals, monitoring recommendations). Include explicit indications, contraindications, and specified monitoring guidance from the label. Remove or reframe non-supported citrus-fruit interaction assertions.